Which of the following drugs is associated with a low risk of hyperlipidemia?

Lurasidone (Latuda) is associated with a low risk of hyperlipidemia, making it the correct choice. This atypical antipsychotic is known for its relatively favorable metabolic profile compared to other medications in the same class. Studies have indicated that lurasidone is less likely to cause weight gain and dyslipidemia, which includes elevated cholesterol and triglyceride levels.

In contrast, other options present a higher risk for metabolic issues. Iloperidone (Fanapt) has been shown to have an increased potential for weight gain and lipid profile changes. Aripiprazole (Abilify), although it is often touted for a lower risk of weight gain compared to other antipsychotics, still presents some risk for hyperlipidemia, particularly in certain populations or dosages. Risperidone is associated with a higher likelihood of weight gain and metabolic syndrome, contributing to increased cholesterol levels.

Understanding the metabolic side effects of antipsychotic medications is crucial for psychiatric-mental health nurse practitioners, especially when considering long-term treatment strategies that aim to minimize risks associated with metabolic syndrome and ensure patient safety.